Generic Name and Formulations:
Sucralfate 1g; scored tabs.
Indications for CARAFATE:
Short-term (up to 8 weeks) treatment of active duodenal ulcer. Maintenance of healed duodenal ulcers (tabs only).
Active: 1g 4 times daily on an empty stomach for 4–8 weeks. Maintenance: 1g 2 times daily.
Susp: administer by oral route only; do not give intravenously. Monitor for glycemia in diabetic patients. Chronic renal failure. Dialysis. Tabs: swallowing impairment (eg, recent or prolonged intubation, tracheostomy, history of aspiration, dysphagia, others). Pregnancy (Cat.B). Nursing mothers.
Avoid antacids within 30mins of dosing. May reduce absorption of tetracyclines, quinidine, levothyroxine, phenytoin, cimetidine, digoxin, ciprofloxacin, norfloxacin, ketoconazole, ranitidine, theophylline; dose concomitant drugs 2hrs before sucralfate. Additive aluminum load with aluminum-containing antacids. Monitor warfarin.
Endocrinology Advisor Articles
- Heritability of BMI Stronger in Obesogenic Environments
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Maternal Gluten Intake Associated With Risk for Type 1 Diabetes in Offspring
- Patterns of Evidence-Based Diabetes Interventions at Local Health Departments
- Bone-Derived Factors in the Treatment of Diabetes
- Vitamin D Supplementation Has No Effect on Musculoskeletal Health
- Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy
- Industry-Funded Trials Often Involve Employees in Studies
- Nutrition Tips for Physicians: Staying Healthy During Busy Days
- Early-Onset Asthma/Wheezing Associated With Later Childhood Obesity